Adult Dosing

Hypotension

• 25-50 mg SC. Give 25-50 mg IM/IV if rapid effect is needed; may give 10-25 by IV push
• May give additional doses at 5-10 mins intervals. Max: 150 mg/24 hrs

Bronchospasm

• 12.5 to 25 mg SC/IM/IV according to patient response

Pediatric Dosing

Hypotension

• 0.5 mg/kg IM/SC of body weight or 16.7 mg/square m² IM/SC q4-6 hours

• Anesthesia-related hypotension
• Acute broncospasm

• Hypersensitivity to any of the ingredients of the product
• Use with halothane or cyclopropane
• Diabetes
• Angle-closure glaucoma
• MAO inhibitor use within 2 wks
• Breastfeeding
• Hyperthyroidism
• Thyrotoxicosis
• CAD
• HTN
• Arrhythmias
• Urinary retention
• Use in obstetrics when maternal blood pressure is in excess of 130/80

• N/A

Renal Dose Adjustment (Based on CrCl)

• Renal impairment: Dose adjustments not defined

Hepatic Dose Adjustment

• Hepatic impairment: Dose adjustments not defined

• Carefully administer therapy in patients with heart disease, angina pectoris, diabetes, hyperthyroidism, prostatic hypertrophy or hypertension and to patients receiving digitalis
• Chronic use of therapy may produce a syndrome resembling an anxiety state
• Tolerance to ephedrine may develop, but temporary discontinuance to the drug restores its original effectiveness

Cautions: Use cautiously in

• Renal impairment
• Cardiovascular disorders
• Diabetes mellitus
• Angle-closure glaucoma
• Seizure disorder
• Prostatic hypertrophy
• Prolonged use
• Patients <6 yrs

Pregnancy Category:C

Breastfeeding: Ephedrine is excreted in breast milk. Due to the potential for serious adverse reactions in nursing infants, manufacturer recommends discontinuation of nursing or discontinuation of drug, taking into account the importance of the drug to the mother.

• CV: Arrhythmias, HTN, MI, palpitations, tachycardia, elevated BP, precordial pain, drug abuse and dependence, paranoid schizophrenia
• CNS: Stroke, seizures, insomnia, headache, dizziness, CNS stimulation, anxiety, tremor, nervousness, vertigo
• GI: Nausea, vomiting, anorexia
• HEPA: Hepatotoxicity
• GU: Nephrotoxicity, urinary retention, painful urination
• DERM: Sweating

• Vasopressor; it has sympathomimetic action. It stimulates alpha adrenergic receptors and causes relaxation of smooth muscle
• Metabolized by liver
• Excreted unchanged in urine
• Half-life: 3-6 hrs

US Trade Name(s)

• Only generic available

US Availability

ephedrine (generic)

• SOLN for INJ: 50 mg/mL (1 mL vial)

Canadian Trade Name(s)

• Only generic available

Canadian Availability

ephedrine

• SOLN for INJ: 50 mg/mL

UK Trade Name(s)

• N/A

UK Availability

• N/A

Australian Trade Name(s)

• Only generic available

Australian Availability

ephedrine

• SOLN for INJ: 30 mg/mL

Cardiovascular

Vasopressors

Infectious Disease

Vasopressors

ENT

Decongestants

Pulmonary

Decongestants

Drug Name: EPHEDRINE SULFATE 25 mg

Ingredient(s): N/A

Imprint: N/A

Color(s): Pink

Shape: Capsule

Size (mm): 15.00

Score: 1

Inactive Ingredient(s): colloidal silicon dioxide / starch, corn / magnesium stearate / fd&c red no. 3 / gelatin

Drug Label Author:
West-ward Pharmaceutical Corp

DEA Schedule:
Non-Scheduled